The role of positron emission tomography following radiosurgical treatment of malignant lung lesions

Nuclear Medicine Communications

Volumn 33, Issue 6, 2012, Pages 607-612

  Gill, Beant Singh ^a   Rivandi, Ali Hosseini ^a   Sandhu, Sameer Pal ^a   Jensen, Lindsay G ^a   Nobiensky, Polly D ^a   Hoh, Carl K ^a   Sandhu, Ajay Pal ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

local control; lung cancer; lung metastases; non small cell lung cancer; positron emission tomography; radiosurgery; standardized uptake value; stereotactic body radiotherapy

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ALLERGIC PNEUMONITIS; ATELECTASIS; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DYSPNEA; FEMALE; HEMOPTYSIS; HUMAN; LOCAL FAILURE FREE SURVIVAL; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RADIATION DOSE FRACTIONATION; RADIOLOGIST; RADIOSURGERY; REVIEW; RIB FRACTURE; SKIN MANIFESTATION; STATISTICAL ANALYSIS; STEREOTACTIC BODY RADIATION THERAPY; TISSUE REACTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; RADIOSURGERY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84860810865     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283512b08     Document Type: Review

References (25)

1. National Comprehensive Cancer Network: non-small cell lung cancers, in Clinical Practice Guidelines in Oncology, 2011, version 3.2011. http://www.nccn.org. [Accessed 5 January 2011].
2. Konski AA, Wallner PE, Harris EER, Price RA, Buyyounouski M, Balter P, et al. Stereotactic body radiotherapy (SBRT) for lung cancer: Report of the ASTRO emerging technology committee. ASTRO 2010;1-42.
3. Sibley GS, Jamieson TA, Marks LB, Anscher MS, Prosnitz LR. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience. Int J Radiat Oncol Biol Phys 1998; 40:149-154. (Pubitemid 28027580)
4. Fakiris AJ, McGarry RC, Yiannoutsos CT, Papiez L, Williams M, Henderson MA, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 2009; 75:677-682.
5. Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007; 2:S94-S100. (Pubitemid 47183602)
6. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010; 303:1070-1076.
7. Nath SK, Sandhu AP, Kim D, Bharne A, Nobiensky PD, Lawson JD, et al. Locoregional and distant failure following image-guided stereotactic body radiation for early-stage primary lung cancer. Radiother Oncol 2011; 99:12-17.
8. Aoki T, Nagata Y, Negoro Y, Takayama K, Mizowaki T, Kokubo M, et al. Evaluation of lung injury after three-dimensional conformal stereotactic radiation therapy for solitary lung tumors: CT appearance. Radiology 2004; 230:101-108. (Pubitemid 37549789)
9. 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy. Ann Nucl Med 2004;669-674. (Pubitemid 40215915)
10. Bradley J. Radiographic response and clinical toxicity following SBRT for stage I lung cancer. J Thorac Oncol 2007; 2:S118-S124. (Pubitemid 47183606)
11. Yeung HW, Schoder H, Smith A, Gonen M, Larson SM. Clinical value of combined positron emission tomography/computed tomography imaging in the interpretation of 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography studies in cancer patients. Mol Imaging Biol 2005; 7: 229-235. (Pubitemid 41348865)
12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
13. Henderson MA, Hoopes DJ, Fletcher JW, Lin PF, Tann M, Yiannoutsos CT, et al. A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010; 76:789-795.
14. Vahdat S, Oermann EK, Collins SP, Yu X, Abedalthagafi M, DeBrito P, et al. Cyberknife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment. J Hematol Oncol 2010; 3:1-6.
15. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50:122S-150S.
16. Coon D, Gokhale AS, Burton SA, Heron DE, Ozhasoglu C, Christie N. Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: the role of positron emission tomography/computed tomography-based treatment planning. Clin Lung Cancer 2008; 9:217-221.
17. Watkins WT, Li R, Lewis J, Park JC, Sandhu A, Jiang SB, et al. Patient-specific motion artifacts in 4DCT. Med Phys 2010; 37:2855-2861.
18. Nath SK, Sandhu AP, Jensen L, Kim D, Bharne A, Nobiensky PD, et al. Frameless image-guided stereotactic body radiation therapy for lung tumors with 4-dimensional computed tomography or 4-dimensional positron emission tomography/computed tomography. Clin Lung Cancer 2011; 12:180-186.
19. Song WY, Kamath S, Ozawa S, Ani SA, Chvetsov A, Bhandare N, et al. A dose comparison study between XVI and OBI CBCT systems. Med Phys 2008; 35:480-486. (Pubitemid 351190867)
20. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007; 48:932-945. (Pubitemid 46909922)
21. Vansteenkiste JF, Stroobants SG. Positron emission tomography in the management of non-small cell lung cancer. Hematol Oncol Clin North Am 2004; 18:269-288. (Pubitemid 38201560)
22. Dahele M, Freeman M, Pearson S, Brade A, Cho BCJ, Hope A, et al. Early metabolic response evaluation after stereotactic radiotherapy for lung cancer: pilot experience with 18F-fluorodeoxyglucose positron emission tomography-computed tomography. Clin Oncol 2011; 23: 359-363.
23. Mohammed N, Grills IS, Wong CO, Galerani AP, Chao K, Welsh R, et al. Radiographic and metabolic response rates following image-guided stereotactic radiotherapy for lung tumors. Radiother Oncol 2011; 99: 18-22.
24. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. J Clin Oncol 1999; 17:3201-3206. (Pubitemid 29470652)
25. Hoopes DJ, Tann M, Fletcher JW, Forquer JA, Lin PF, Lo SS, et al. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. Lung Cancer 2007; 56:229-234. (Pubitemid 46590486)